FDA Approves Treatment for Rare Genetic Disorder

News
Article

The approval of Givlaari (givosiran) is the first for treatment of acute hepatic porphyria, which results in the buildup of toxic porphyrin molecules during the production of heme.

FDA announced on Nov. 20, 2019 that it has approved Givlaari (givosiran) for the treatment of acute hepatic porphyria, a genetic disorder that results in the buildup of toxic porphyrin molecules during the production of heme. The application was granted through the agency’s Breakthrough Therapy, Priority Review, and Orphan Drug designations.

A buildup of toxic porphyrin molecules causes attacks that can lead to severe pain, paralysis, respiratory failure, seizures, and changes in mental status, according to Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Prior to today’s approval, treatment options have only provided partial relief from the intense unremitting pain that characterizes these attacks. The drug approved today can treat this disease by helping to reduce the number of attacks that disrupt the lives of patients,” Pazdur stated in a press release.

The agency based the approval on the results of a clinical trial that involved 94 patients with the disorder. The study measured the performance of the drug by the rate of porphyria attacks that required hospitalization, urgent healthcare visits, or intravenous infusion of hema. According to FDA, 70% fewer attacks were seen in patients who received Givlaari compared to those that received a placebo.

Source: FDA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes